To evaluate these therapies, it helps to first define what they are and establish their current clinical availability
Other health risks include: Pancreatitis: Some studies suggest a possible link between GLP-1s and inflammation of the pancreas, though the risk appears to be low
Full-stomach precautions may include rapid sequence induction when appropriate, airway-protective strategies, suction readiness, careful positioning, and consideration of awake intubation in selected difficult-airway/high-aspiration-risk scenarios
Neural regulation of pancreatic islet cell mass and function
Their primary therapeutic effects include glucose-dependent insulin secretion from pancreatic beta cells, suppression of inappropriate glucagon release, delayed gastric emptying, and reduced appetite through central nervous system pathways
The Phase 2 trial published in the New England Journal of Medicine in 2023 reported up to 24% average weight loss at 48 weeks at the highest dose the largest number ever recorded for an obesity drug
